默沙东(MRK.US)新冠口服药有效减少34%住院风险

智通财经2022-06-07

智通财经APP获悉，据3期MOVe-OUT试验数据表明，默沙东(MRK.US)和Ridgeback Biotherapeutics两家公司共同开发的新冠口服药将急性护理就诊风险降低了近34%。Lagevrio(molnupiravir)于去年12月在美国被授权用于治疗有发生严重疾病风险的轻度至中度新冠的非住院成人患者。数据显示，在接受一剂治疗后的第29天，只有7.2%的Lagevrio治疗受试者...

网页链接

免责声明：本文观点仅代表作者个人观点，不构成本平台的投资建议，本平台不对文章信息准确性、完整性和及时性做出任何保证，亦不对因使用或信赖文章信息引发的任何损失承担责任。

精彩评论

我们需要你的真知灼见来填补这片空白

发表看法

{"i18n":{"language":"zh_CN"},"isChannel":false,"data":{"share":"https://www.laohu8.com/m/news/2241711540?lang=zh_CN&edition=full","thumbnail":"","is_english":false,"pubTime":"2022-06-07 21:05","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2241711540","market":"hk","top_or_hot":-1,"title":"默沙东(MRK.US)新冠口服药有效减少34%住院风险","media":"智通财经","content":"<div>\n<p>智通财经APP获悉，据3期MOVe-OUT试验数据表明，默沙东(MRK.US)和Ridgeback Biotherapeutics两家公司共同开发的新冠口服药将急性护理就诊风险降低了近34%。Lagevrio(molnupiravir)于去年12月在美国被授权用于治疗有发生严重疾病风险的轻度至中度新冠的非住院成人患者。数据显示，在接受一剂治疗后的第29天，只有7.2%的Lagevrio治疗受试者...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/735118.html\">网页链接</a>\n\n</div>\n","source":"stock_zhitongcaijing","html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>默沙东(MRK.US)新冠口服药有效减少34%住院风险</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\n默沙东(MRK.US)新冠口服药有效减少34%住院风险\n</h2>\n\n<h4 class=\"meta\">\n\n\n2022-06-07 21:05 北京时间&nbsp;&nbsp;&nbsp;<a href=http://www.zhitongcaijing.com/content/detail/735118.html><strong>智通财经</strong></a>\n\n\n</h4>\n\n</header>\n<article>\n<div>\n<p>智通财经APP获悉，据3期MOVe-OUT试验数据表明，默沙东(MRK.US)和Ridgeback Biotherapeutics两家公司共同开发的新冠口服药将急性护理就诊风险降低了近34%。Lagevrio(molnupiravir)于去年12月在美国被授权用于治疗有发生严重疾病风险的轻度至中度新冠的非住院成人患者。数据显示，在接受一剂治疗后的第29天，只有7.2%的Lagevrio治疗受试者...</p>\n\n<a href=\"http://www.zhitongcaijing.com/content/detail/735118.html\">网页链接</a>\n\n</div>\n\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"BK4559","symbol_name":"巴菲特持仓","start_time":0,"source_url":"http://www.zhitongcaijing.com/content/detail/735118.html","article_id":"2241711540","we_media_id":null,"thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2241711540","pubTimestamp":1654607118,"sourceInfo":{"source_id":"stock_zhitongcaijing","name":"智通财经网"},"weMediaInfo":null,"summary":"智通财经APP获悉，据3期MOVe-OUT试验数据表明，默沙东和Ridgeback Biotherapeutics两家公司共同开发的新冠口服药将急性护理就诊风险降低了近34%。Lagevrio于去年12月在美国被授权用于治疗有发生严重疾病风险的轻度至中度新冠的非住院成人患者。默沙东和Ridgeback表示，截至5月31日，两家公司已向全球30多个政府提供了超过800万个治疗方案。辉瑞本周一宣布投资1.2亿美元以扩大美国COVID-19口服药的生产，并在37个国家/地区提供了1200万个疗程。","collect":0,"end_time":0,"defaultTopTitle":"zhitongcaijing.com","property":[],"viewcount":null,"language":"zh","relate_stocks":{"BK4559":"巴菲特持仓","BK4534":"瑞士信贷持仓","BK4550":"红杉资本持仓","BK4533":"AQR资本管理(全球第二大对冲基金)","MRK":"默沙东","BK4007":"制药","BK4516":"特朗普概念"},"translate_title":"Mercadon (MRK.US) COVID-19 Oral Administration Effectively Reduces Hospitalization Risk by 34%","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"MRK":1},"content_text":"智通财经APP获悉，据3期MOVe-OUT试验数据表明，默沙东(MRK.US)和Ridgeback Biotherapeutics两家公司共同开发的新冠口服药将急性护理就诊风险降低了近34%。Lagevrio(molnupiravir)于去年12月在美国被授权用于治疗有发生严重疾病风险的轻度至中度新冠的非住院成人患者。数据显示，在接受一剂治疗后的第29天，只有7.2%的Lagevrio治疗受试者报告了急性护理就诊，而安慰剂参与者的对应比例为10.6%，相对风险降低(RRR)为32.1%。与此同时，6.6%的Lagevrio受试者报告了与COVID-19相关的急性护理就诊，而安慰剂组为10.0%，RRR为33.8%。此外，接受Lagevrio的住院患者可能比接受安慰剂的患者提前3天离开医院。默沙东和Ridgeback表示，截至5月31日，两家公司已向全球30多个政府提供了超过800万个治疗方案。辉瑞(PFE.US)本周一宣布投资1.2亿美元以扩大美国COVID-19口服药的生产，并在37个国家/地区提供了1200万个疗程。","kind":null,"is_publish_news":null,"is_publish_highlight":null,"is_publish_live":null,"is_publish_wemedia":null,"editions":null,"symbols":[],"gpt_button":1},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":false,"deviceId":"web-server-community-laohu8-v3","version":"4.22.4","shortVersion":"4.22.4","platform":"web","vendor":"web","appName":"laohu8","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/2241711540"}